Return to homepagePandemic Pact

Development of recombinant adeno-associated virus [rAAV] based genetic vaccine for COVID-19

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    BIRAC

  • Principal Investigator

    Lakshmikanth Gandikota

  • Research Location

    India

  • Lead Research Institution

    Intas Pharmaceuticals Ltd.

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    Innovation

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

10 of the total COVID-19 infections are reported from India. Recently approved, all the first-generation vaccines have some concerns related to its supply logistics meeting supply and demand, reliance on 1 injection and thermostability and long-term safety and efficacy reactogenicity, durability of immune responses, and efficacy in immunocompromised, elderly, obese and pregnant populations . Additionally, little is known about important factors expenses and reliability of scale-up manufacturing critical in assessing the feasibility of using any vaccine in global vaccine campaigns. Therefore, development of rAAV-based highly safe and efficacious single dose second-generation vaccine is important to overcome some of the above limitations.